Yıldız, O. et al. 2026. Reduced efficacy of nivolumab following prior immunotherapy in metastatic renal cell carcinoma: Implications for sequential immune checkpoint inhibition. EXPERIMENTAL BIOMEDICAL RESEARCH. 9, 1 (Jan. 2026), 1–9. DOI:https://doi.org/10.30714/j-ebr.2026.262.